Holdings announced a broad strategic collaboration with Hologen. MeiraGTx will receive $200 million in upfront cash at closing ...

Reports FY24 revenue $33.279M vs $14.017M last year. “MeiraGTx (MGTX) demonstrated excellent execution in 2024, marked by significant ...

MeiraGTx’s investigational gene therapy AAV-AIPL1 has improved the sight of 11 children who were born blind. As disclosed in the paper, 4 out of 4 young children with the AIPL1-related retinal ...

Armed with data from a small phase 1/2 bridging study, MeiraGTx is preparing to take its gene therapy for Parkinson's disease into a pivotal trial. Shares in the Anglo-US biotech rose sharply ...

Pre-Market: 5:28:26 a.m. EDT Loading Chart for MGTX ...

Research reports are not currently available for MGTX.